{"id":"W2100615084","doi":"10.1111/j.1365-2265.2009.03620.x","title":"A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long‐acting octreotide in patients with acromegaly","year":2009,"lang":"en","type":"article","venue":"Clinical Endocrinology","topic":"Pituitary Gland Disorders and Treatments","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"Novo Nordisk; National Institutes of Health; Pfizer; Eli Lilly and Company","keywords":"Pegvisomant; Medicine; Acromegaly; Adverse effect; Internal medicine; Octreotide; Randomized controlled trial; Gastroenterology; Somatostatin; Endocrinology; Growth hormone; Hormone","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00254238,0.002128888,0.0045614,0.0005315872,0.0005550219,0.001260942,0.001529213,0.00243415,0.006392269],"category_scores_gemma":[0.00346293,0.001014725,0.002001453,0.000610013,0.001711789,0.001286557,0.0006308989,0.002862198,0.001121961],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009727311,"about_ca_system_score_gemma":0.001780092,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008544148,"about_ca_topic_score_gemma":0.001564213,"domain_scores_codex":[0.9984136,0.0009894177,0.00009901184,0.0002650051,0.00008814783,0.0001447618],"domain_scores_gemma":[0.9976019,0.0007494024,0.0006139898,0.0001994963,0.0001302978,0.0007048812],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9926811,0.002821573,0.0002372903,0.0001384623,0.0002736576,0.00001682076,0.00001388412,0.0001006705,0.0006619037,0.00002130976,0.0001629046,0.002870425],"study_design_scores_gemma":[0.9635862,0.03536572,0.0005166691,0.000007653765,0.0001349498,0.00001477831,0.000006296026,0.0001466004,0.00007482526,0.00002565467,0.0001158864,0.000004789732],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9879154,0.003456582,0.0005873594,0.0006330531,0.0006481459,0.004580015,0.0006514209,0.0001044719,0.001423447],"genre_scores_gemma":[0.9852945,0.001576932,0.002249217,0.001156245,0.0006947409,0.006481872,0.0008581788,0.00002419962,0.001664113],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006392269,"threshold_uncertainty_score":0.0213843,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02594826122174928,"score_gpt":0.3208575987697698,"score_spread":0.2949093375480205,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}